Sarepta Therapeutics (SRPT) Amortization - Intangibles (2017 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Amortization - Intangibles of $691000.0 for Q1 2026, up 14.98% year-over-year from $601000.0 in Q1 2025, and up 2.07% quarter-over-quarter from $677000.0 in Q4 2025.
Sarepta Therapeutics (SRPT) Amortization - Intangibles (2017 - 2026) Analysis & Trends
Sarepta Therapeutics' Amortization - Intangibles history runs 10 years deep, the most recent figure standing at $691000.0 for Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 14.98% year-over-year to $691000.0; the TTM figure through Mar 2026 stood at $2.7 million (up 12.77% YoY), while the FY2025 annual figure was $2.6 million, up 9.02% from the prior year.
- Amortization - Intangibles for Q1 2026 stood at $691000.0, up from $677000.0 in the prior quarter.
- The five-year high for Amortization - Intangibles was $763000.0 in Q4 2023, with the low at $178000.0 in Q1 2022.
- The 5-year median for Amortization - Intangibles is $601000.0 (2024), against an average of $470058.8.
- The sharpest annual moves came in 2023 and 2024: Amortization - Intangibles surged 326.26% in 2023, then declined 21.23% in 2024.
- Sarepta Therapeutics' Amortization - Intangibles stood at $179000.0 in 2022, then jumped by 326.26% to $763000.0 in 2023, then slipped by 21.23% to $601000.0 in 2024, then rose by 12.65% to $677000.0 in 2025, then increased by 2.07% to $691000.0 in 2026.
- Business Quant data shows SRPT's Amortization - Intangibles at $691000.0 in Q1 2026, $677000.0 in Q4 2025, and $677000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 717,000.00 |
| Mar 31, 2026 | 691,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | 677,000.00 |
| Jun 30, 2025 | 667,000.00 |
| Mar 31, 2025 | 601,000.00 |
| Dec 31, 2024 | 601,000.00 |
| Sep 30, 2024 | 602,000.00 |
| Jun 30, 2024 | 601,000.00 |
| Mar 31, 2024 | 601,000.00 |
| Dec 31, 2023 | 763,000.00 |
| Sep 30, 2023 | 439,000.00 |
| Jun 30, 2023 | 179,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Dec 31, 2022 | 179,000.00 |
| Sep 30, 2022 | 178,000.00 |
| Jun 30, 2022 | 179,000.00 |
| Mar 31, 2022 | 178,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2021 | 178,000.00 |